论文部分内容阅读
目的:研究给CHF并发心律失常患者实施芪参益气滴丸和酒石酸美托洛尔联合治疗的效果。方法:从2011年1月至2014年1月到院就医的慢性充血性心力衰竭(CHF)伴发心律失常患者120例,依照治疗方案的不同,把接受酒石酸美托洛尔治疗的62名患者归为对照组,接受芪参益气滴丸和酒石酸美托洛尔联合治疗的58名患者归为试验组。对医疗效果进行对比分析。结果:对照组患者的总有效率为77.4%,显效率是47.6%,无效占比例的22.6%,而试验组的总有效率为96.5%,显效率是66.4%,无效占比例的3.5%。试验组的总有效率和显效率明显高于对照组,无效率也比对照组大大降低。治疗前后对照组和试验组患者早搏频率变化均得到改善(P<0.05),而试验组患者的改善更为明显(P<0.01)。患者在两组治疗中均无严重不良反应以及并发症。结论:将芪参益气滴丸联合应用到CHF并发心律失常患者治疗上,疗效明显比酒石酸美托洛尔治疗好,联合治疗可以更好地控制心率失常症状的发生。
Objective: To study the effect of Qishen Yiqi drop pills combined with metoprolol tartrate on patients with CHF complicated with arrhythmia. Methods: From January 2011 to January 2014, 120 patients with chronic congestive heart failure (CHF) accompanied by arrhythmia admitted to hospital were enrolled. According to the different treatment plans, 62 patients receiving metoprolol tartrate As a control group, 58 patients receiving combined treatment of Qishenyiqi drops and metoprolol tartrate were included in the experimental group. The comparative analysis of medical effects. Results: The total effective rate of the control group was 77.4%, markedly effective rate was 47.6% and invalid ratio was 22.6%. The total effective rate was 96.5% in the control group, markedly effective rate was 66.4% and invalid rate was 3.5%. The total effective rate and markedly effective rate of the experimental group was significantly higher than that of the control group, and the inefficiency was significantly lower than that of the control group. Before and after treatment, the changes of premature beat frequency in control group and experimental group were improved (P <0.05), while those in experimental group were more obvious (P <0.01). The patients had no serious adverse reactions and complications in both groups. Conclusion: The combination of Qishenyiqi dripping pill in patients with CHF complicated with arrhythmia was significantly better than metoprolol tartrate. The combination therapy could better control the incidence of arrhythmia.